WHY?
-
Identifying patients at risk of failing, or who have failed, TKI treatment allows physicians to change therapy earlier in the treatment course to improve long-term outcomes1,2
WHAT?
-
Molecular monitoring by RQ-PCR is recommended at baseline and at least every 3 months throughout treatment1
-
Monitoring schedule has to be adapted for patients who cease therapy (TFR patients)1